Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
 Annual Conference - EconoTimes)
CAMBRIDGE, Mass., April 06, 2016 -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a central organ for devastating rare diseases, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will deliver a presentation titled, “Developing an AAV Pipeline and Building a Successful Biotech,” during the BSGCT Annual Conference – AAV in 2016: Biology, vector design and implementation into human gene therapy. The conference will take place at the University College London Institute of Child Health on Friday, April 15, 2016. Dr. Jenkins’ presentation will begin at 1:45pm BST.
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency and GSDIa, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
CONTACT: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 [email protected] Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 [email protected]
